Grzegorz Nowakowski

Dr. Mark Roschewski, a clinical investigator at the National Cancer Institute, Dr. Grzegorz Nowakowski from Mayo Clinic, and Dr. Neha Mehta-Shah, an associate professor at Washington University, discuss aggressive non-Hodgkin lymphoma. They highlight the importance of identifying high-risk patients for tailored treatments. The conversation delves into the unique challenges of lymphomas in immune-privileged sites and innovative therapies like BTK inhibitors. They also touch on new options like Polar-RCHIP and the promise of circulating tumor DNA in clinical trials.